NCT05135871View on ClinicalTrials.gov

Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

45

Participants

Timeline

Start Date

October 31, 2021

Primary Completion Date

February 5, 2022

Study Completion Date

February 28, 2022

Conditions

Hypertrophic Cardiomyopathy

Interventions

DRUG

Mavacamten

Single fasted oral dose of Mavacamten 15/25 mg on Day 1

Trial Locations (1)

200040

Huashan Hospital Fudan University, Shanghai

Sponsors

Lead Sponsor

All Listed Sponsors

lead

LianBio LLC

INDUSTRY